Cargando…

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction associated fatty liver disease (MAFLD) have important associations with cardiovascular disease (CVD). The main objective of this study was to compare the frequency of incidence rate of CVD in the NAFLD or MAFLD patients u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoneda, Masato, Yamamoto, Takuma, Honda, Yasushi, Imajo, Kento, Ogawa, Yuji, Kessoku, Takaomi, Kobayashi, Takashi, Nogami, Asako, Higurashi, Takuma, Kato, Shingo, Hosono, Kunihiro, Saito, Satoru, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531127/ https://www.ncbi.nlm.nih.gov/pubmed/34601620 http://dx.doi.org/10.1007/s00535-021-01828-6

Ejemplares similares

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
por: Terai, Shuji, et al.
Publicado: (2021)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model
por: Hasebe, Takumu, et al.
Publicado: (2016)

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
por: Wong, Robert J., et al.
Publicado: (2021)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response
por: Tang, Li, et al.
Publicado: (2009)

Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation
por: Hiraoka, Atsushi, et al.
Publicado: (2015)

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure
por: Xu, Zhihui, et al.
Publicado: (2010)

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice
por: Ono, Masafumi, et al.
Publicado: (2013)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients
por: Mowry, Christopher J., et al.
Publicado: (2021)

Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2018)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
por: Yoneda, Masato, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease: new treatments
por: Hardy, Timothy, et al.
Publicado: (2015)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

Long-term Prognosis of Acute-on-Chronic Liver Failure Survivors
por: Yoon, Eileen L., et al.
Publicado: (2019)

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
por: Enomoto, Hirayuki, et al.
Publicado: (2019)

CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness
por: Song, Yan, et al.
Publicado: (2020)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

Spleen Stiffness Differentiates Between Acute and Chronic Liver Damage and Predicts Hepatic Decompensation
por: Meister, Phil, et al.
Publicado: (2019)

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
por: Enomoto, Hirayuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pe9ksj6ue1n66bmqsm4iqfupc5